T
Tejal N Gandhi
Researcher at University of Michigan
Publications - 40
Citations - 1834
Tejal N Gandhi is an academic researcher from University of Michigan. The author has contributed to research in topics: Antimicrobial stewardship & Pneumonia. The author has an hindex of 12, co-authored 32 publications receiving 1233 citations.
Papers
More filters
Journal ArticleDOI
Impact of Rapid Organism Identification via Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Combined With Antimicrobial Stewardship Team Intervention in Adult Patients With Bacteremia and Candidemia
Angela M. Huang,Duane W. Newton,Anjly Kunapuli,Tejal N Gandhi,Laraine Washer,Jacqueline Isip,Curtis D. Collins,Jerod Nagel +7 more
TL;DR: MALDI-TOF with AST intervention decreased time to organism identification and time to effective and optimal antibiotic therapy and acceptance of an AST intervention was associated with a trend toward reduced mortality on multivariable analysis.
Journal ArticleDOI
Tocilizumab for treatment of mechanically ventilated patients with COVID-19.
Emily C. Somers,Gregory A. Eschenauer,Jonathan P. Troost,Jonathan L. Golob,Tejal N Gandhi,Lu Wang,Nina Zhou,Lindsay A Petty,Ji Hoon Baang,Nicholas O Dillman,David Frame,Kevin S. Gregg,Dan R Kaul,Jerod Nagel,Twisha S Patel,Shiwei Zhou,Adam S. Lauring,David A. Hanauer,Emily T. Martin,Pratima Sharma,Christopher Fung,Jason M. Pogue +21 more
TL;DR: In this cohort of mechanically ventilated COVID-19 patients, tocilizumab was associated with lower mortality despite higher superinfection occurrence.
Journal ArticleDOI
Empiric Antibacterial Therapy and Community-onset Bacterial Coinfection in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19): A Multi-hospital Cohort Study.
Valerie M. Vaughn,Tejal N Gandhi,Lindsay A Petty,Payal K. Patel,Hallie C. Prescott,Anurag N. Malani,David Ratz,Elizabeth McLaughlin,Vineet Chopra,Scott A. Flanders +9 more
TL;DR: The prevalence of confirmed community-onset bacterial coinfections was low and half of patients received early empiric antibacterial therapy, and reducing COVID-19 test turnaround time and supporting stewardship could improve antibacterial use.
Posted ContentDOI
Tocilizumab for treatment of mechanically ventilated patients with COVID-19
Emily C. Somers,Gregory A. Eschenauer,Jonathan P. Troost,Jonathan L. Golob,Tejal N Gandhi,Lu Wang,Nina Zhou,Lindsay A Petty,Ji Hoon Baang,Nicholas O Dillman,David Frame,Kevin S. Gregg,Dan R Kaul,Jerod Nagel,Twisha S Patel,Shiwei Zhou,Adam S. Lauring,David A. Hanauer,Emily T. Martin,Pratima Sharma,Christopher Fung,Jason M. Pogue +21 more
TL;DR: In this cohort of mechanically ventilated COVID-19 patients, tocilizumab was associated with a decreased likelihood of death despite higher superinfection occurrence.
Journal ArticleDOI
Excess Antibiotic Treatment Duration and Adverse Events in Patients Hospitalized With Pneumonia: A Multihospital Cohort Study.
Valerie M. Vaughn,Scott A. Flanders,Ashley Snyder,Anna Conlon,Mary A.M. Rogers,Anurag N. Malani,Elizabeth McLaughlin,Sarah Bloemers,Arjun Srinivasan,Jerod Nagel,Scott Kaatz,Danielle Osterholzer,Rama Thyagarajan,Lama Hsaiky,Vineet Chopra,Tejal N Gandhi +15 more
TL;DR: An ongoing cohort study of medical patients hospitalized with community-acquired pneumonia or health careassociated pneumonia in 43 hospitals across Michigan was used to quantify excess antibiotic treatment duration, determine factors associated with it, and evaluate its relationship with outcomes.